Expression of erythropoietin by the human placenta

Abstract

Circulating levels of maternal erythro‐poietin (EPO) rise during gestation due to increased biosynthesis of the hormone. Our objective was to investigate the human placenta as a potential extrarenal site of EPO production. Using two mono‐clonal antibodies recognizing different antigenic determinants, we identified immunoreactive EPO associated with villous cytotrophoblast, endovascular and intravascular cytotrophoblast, cytotrophoblast cell columns, and syncytiotrophoblast of first and second‐trimester placenta as well as syncytiotro‐ phoblast and extravillous cytotrophoblast of normal third‐trimester and preeclamptic placenta. In addi‐tion, cultured JAR (trophoblast‐derived) choriocar‐cinoma cells, cytotrophoblasts isolated from term placenta, villous core cells, and possibly other non‐ trophoblast cells within the decidual basal plate ex‐pressed immunoreactive EPO. Using reverse transcription‐polymerase chain reaction and EPO‐ specific primers, a 378 bp DNA product was ampli‐fied from placental tissues of various gestational ages, cytotrophoblasts isolated from term placenta, and JAR choriocarcinoma cells. The amplified product yielded restriction enzyme fragments of predicted sizes. On Southern analysis, hybridization was observed for two of these fragments in which the radiolabeled EPO cDNA probe did not overlap with the primer sequences. Finally, the JAR choriocarcinoma cells elaborated EPO into the culture medium as determined by enzyme‐linked immunosorbant assay and expressed EPO mRNA as determined by Northern analysis, both of which were stimulated by hypoxia (15‐20 torr). Taken together, these results suggest a new site of EPO expression: the trophoblast cell of the human placenta.—Conrad, K. P., Benyo, D. F., Westerhausen‐Larsen, A., Miles, T. M. Expression of erythropoietin by the human placenta. FASEB J. 10, 760‐766 (1996)